Sangamo Biosciences (SGMO) 15.40 $SGMO
Sangamo BioSciences Presents Data At 11th Annual WorldSymposium(TM) Meeting Supporting In Vivo Protein Replacement Platform Approach For The Treatment Of Lysosomal Storage Disorders
PR Newswire - Thu Feb 12, 6:00AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the presentation of preclinical data from its In Vivo Protein Replacement Platform (IVPRP) program for the development of proprietary ZFP Therapeutics® for the potential cure of lysosomal storage disorders (LSDs). The study was presented at the WORLDSymposium(TM) 2015 Meeting, a multidisciplinary forum presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases, which is being held in Orlando, Florida, from February 9-13, 2015. The data were generated by Sangamo scientists and their collaborators at the University of Minnesota and University of Massachusetts Medical School.
SGMO: 15.40 (+0.14)
4 Stocks Spiking on Big Volume: Akamai, Hydrogenics and More
at The Street - Wed Feb 11, 1:11PM CST
Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
HYGS: 14.25 (-0.28), AKAM: 68.77 (+1.18), SGMO: 15.40 (+0.14), FTI: 41.05 (+1.26)
Why Sangamo Biosciences Inc. Shares Rocketed Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 11, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Sangamo Biosciences shares surged more than 14%...
BIIB: 391.66 (-0.45), SHPG: 239.82 (+6.11), SGMO: 15.40 (+0.14)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 11:45AM CST
JIVE: 5.34 (+0.02), JONE: 10.18 (+0.18), FXEN: 1.99 (+0.10), CDTI: 2.35 (+0.11), SGMO: 15.40 (+0.14), EVRY: 1.00 (-0.04), INXN: 32.04 (+0.14), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), BLDP: 2.66 (-0.26), PNTR: 7.90 (+0.01), PRSS: 2.95 (-0.08), BXE: 2.79 (+0.05), ANTH: 3.84 (+0.06), PIR: 12.52 (+0.17), PSTR: 4.63 (+0.14), MKTO: 28.24 (+0.20), ANDE: 45.11 (+0.71), DGLY: 11.50 (-0.40), DCTH: 1.14 (+0.04)
Sangamo BioSciences ups revenues 117% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 7:55AM CST
SGMO: 15.40 (+0.14)
Sangamo Biosciences' (SGMO) CEO Edward Lanphieron Q4 2014Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 6:56PM CST
SGMO: 15.40 (+0.14)
Sangamo BioSciences (SGMO) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:55PM CST
SGMO: 15.40 (+0.14)
Sangamo BioSciences beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:05PM CST
SGMO: 15.40 (+0.14)
Sangamo BioSciences Reports Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Tue Feb 10, 3:02PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its fourth quarter and full year 2014 financial results and accomplishments.
SGMO: 15.40 (+0.14)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Will Sangamo (SGMO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 12:10PM CST
Sangamo BioSciences, Inc. (SGMO) is scheduled to report fourth-quarter 2014 results on Feb 10, 2015 and holds a Zacks Rank #3 (Hold) with an Earnings ESP of 0.00%.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), SHPG: 239.82 (+6.11), SGMO: 15.40 (+0.14)
AstraZeneca plc Beefs Up Precision Medicine Arsenal
Maxx Chatsko, The Motley Fool - Motley Fool - Mon Feb 09, 6:02AM CST
Novartis : "Hey, everyone, look over here. I just entered into a collaboration that will give me access to a pretty intriguing genome editing tool. Going to combine it with my top pipeline candidate . It's pretty cool." AstraZeneca : "I see your...
ALNY: 95.54 (+1.67), TMO: 127.61 (+0.78), AZN: 69.96 (+0.20), SGMO: 15.40 (+0.14), NVS: 102.20 (-0.17)
Sangamo BioSciences Announces Presentation At The 2015 Leerink Global Healthcare Conference
PR Newswire - Thu Feb 05, 3:02PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:45 am ET on Thursday, February 12, 2015, at the 2015 Leerink Global Healthcare Conference. The conference is being held in New York.
SGMO: 15.40 (+0.14)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
Sangamo BioSciences Announces FDA Acceptance of IND to Initiate Clinical Trial of its Novel ZFP Therapeutic® for Beta-Thalassemia
PR Newswire - Wed Feb 04, 6:00AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration (FDA) and is now active. This enables Sangamo to initiate a Phase 1/2 clinical trial of the ZFP Therapeutic in transfusion-dependent patients with beta-thalassemia major. The trial, which is expected to begin in 2015, is designed to assess the safety and tolerability, and measures of efficacy of this novel approach. Sangamo is developing the therapy in collaboration with Biogen Idec.
BIIB: 391.66 (-0.45), SGMO: 15.40 (+0.14)
Sangamo BioSciences Announces Fourth Quarter and Full Year 2014 Conference Call and Webcast
PR Newswire - Tue Feb 03, 3:02PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the company will release its fourth quarter and full year 2014 financial results after the market closes on Tuesday, February 10, 2015. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 15.40 (+0.14)
The Alliance for Regenerative Medicine Announces Its Third Annual Regen Med Investor Day & Initial Slate of Presenting Companies
GlobeNewswire - Tue Feb 03, 10:44AM CST
via PRWEB - The Alliance for Regenerative Medicine (ARM) today announced its annual Regen Med Investor Day will take place March 25, 2015 in New York City, co-hosted by top financial firm Piper Jaffray. Now in its third year, this one-day meeting remains the only investment event organized specifically to provide institutional, strategic and venture investors with unique insights into the financing hypothesis for advanced therapies-based treatments and technology.
BIIB: 391.66 (-0.45), SGMO: 15.40 (+0.14)
Opko files IND for study of long-acting clotting factor
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 11:31AM CST
BIIB: 391.66 (-0.45), ALNY: 95.54 (+1.67), OPK: 13.80 (-0.28), BAX: 70.39 (+0.31), SGMO: 15.40 (+0.14)
Commit To Buy Sangamo BioSciences At $8, Earn 10.8% Annualized Using Options
at The Street - Thu Jan 22, 10:36AM CST
Investors eyeing a purchase of Sangamo BioSciences Inc shares, but cautious about paying the going market price of $12.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
SGMO: 15.40 (+0.14)
10.0% Return Seen to Date on SmarTrend Sangamo Biosciences Call (SGMO)
Comtex SmarTrend(R) - Wed Jan 21, 5:09PM CST
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on October 28th, 2014 at $12.13. In approximately 3 months, Sangamo Biosciences has returned 10.02% as of today's recent price of $13.34.
SGMO: 15.40 (+0.14)
Sangamo BioSciences Presents Data At 11th Annual WorldSymposium(TM) Meeting Supporting In Vivo Protein Replacement Platform Approach For The Treatment Of Lysosomal Storage Disorders
PR Newswire - Thu Feb 12, 6:00AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the presentation of preclinical data from its In Vivo Protein Replacement Platform (IVPRP) program for the development of proprietary ZFP Therapeutics® for the potential cure of lysosomal storage disorders (LSDs). The study was presented at the WORLDSymposium(TM) 2015 Meeting, a multidisciplinary forum presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases, which is being held in Orlando, Florida, from February 9-13, 2015. The data were generated by Sangamo scientists and their collaborators at the University of Minnesota and University of Massachusetts Medical School.
SGMO: 15.40 (+0.14)
4 Stocks Spiking on Big Volume: Akamai, Hydrogenics and More
at The Street - Wed Feb 11, 1:11PM CST
Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
HYGS: 14.25 (-0.28), AKAM: 68.77 (+1.18), SGMO: 15.40 (+0.14), FTI: 41.05 (+1.26)
Why Sangamo Biosciences Inc. Shares Rocketed Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 11, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Sangamo Biosciences shares surged more than 14%...
BIIB: 391.66 (-0.45), SHPG: 239.82 (+6.11), SGMO: 15.40 (+0.14)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 11:45AM CST
JIVE: 5.34 (+0.02), JONE: 10.18 (+0.18), FXEN: 1.99 (+0.10), CDTI: 2.35 (+0.11), SGMO: 15.40 (+0.14), EVRY: 1.00 (-0.04), INXN: 32.04 (+0.14), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), BLDP: 2.66 (-0.26), PNTR: 7.90 (+0.01), PRSS: 2.95 (-0.08), BXE: 2.79 (+0.05), ANTH: 3.84 (+0.06), PIR: 12.52 (+0.17), PSTR: 4.63 (+0.14), MKTO: 28.24 (+0.20), ANDE: 45.11 (+0.71), DGLY: 11.50 (-0.40), DCTH: 1.14 (+0.04)
Sangamo BioSciences ups revenues 117% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 7:55AM CST
SGMO: 15.40 (+0.14)
Sangamo Biosciences' (SGMO) CEO Edward Lanphieron Q4 2014Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 6:56PM CST
SGMO: 15.40 (+0.14)
Sangamo BioSciences (SGMO) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:55PM CST
SGMO: 15.40 (+0.14)
Sangamo BioSciences beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:05PM CST
SGMO: 15.40 (+0.14)
Sangamo BioSciences Reports Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Tue Feb 10, 3:02PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its fourth quarter and full year 2014 financial results and accomplishments.
SGMO: 15.40 (+0.14)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Will Sangamo (SGMO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 12:10PM CST
Sangamo BioSciences, Inc. (SGMO) is scheduled to report fourth-quarter 2014 results on Feb 10, 2015 and holds a Zacks Rank #3 (Hold) with an Earnings ESP of 0.00%.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), SHPG: 239.82 (+6.11), SGMO: 15.40 (+0.14)
AstraZeneca plc Beefs Up Precision Medicine Arsenal
Maxx Chatsko, The Motley Fool - Motley Fool - Mon Feb 09, 6:02AM CST
Novartis : "Hey, everyone, look over here. I just entered into a collaboration that will give me access to a pretty intriguing genome editing tool. Going to combine it with my top pipeline candidate . It's pretty cool." AstraZeneca : "I see your...
ALNY: 95.54 (+1.67), TMO: 127.61 (+0.78), AZN: 69.96 (+0.20), SGMO: 15.40 (+0.14), NVS: 102.20 (-0.17)
Sangamo BioSciences Announces Presentation At The 2015 Leerink Global Healthcare Conference
PR Newswire - Thu Feb 05, 3:02PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:45 am ET on Thursday, February 12, 2015, at the 2015 Leerink Global Healthcare Conference. The conference is being held in New York.
SGMO: 15.40 (+0.14)
Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics
PR Newswire - Thu Feb 05, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&am...amp;s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
MDVN: 104.71 (+0.67), IMMU: 3.84 (unch), CYTX: 0.47 (unch), AMRN: 1.18 (unch), SGMO: 15.40 (+0.14)
Sangamo BioSciences Announces FDA Acceptance of IND to Initiate Clinical Trial of its Novel ZFP Therapeutic® for Beta-Thalassemia
PR Newswire - Wed Feb 04, 6:00AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration (FDA) and is now active. This enables Sangamo to initiate a Phase 1/2 clinical trial of the ZFP Therapeutic in transfusion-dependent patients with beta-thalassemia major. The trial, which is expected to begin in 2015, is designed to assess the safety and tolerability, and measures of efficacy of this novel approach. Sangamo is developing the therapy in collaboration with Biogen Idec.
BIIB: 391.66 (-0.45), SGMO: 15.40 (+0.14)
Sangamo BioSciences Announces Fourth Quarter and Full Year 2014 Conference Call and Webcast
PR Newswire - Tue Feb 03, 3:02PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the company will release its fourth quarter and full year 2014 financial results after the market closes on Tuesday, February 10, 2015. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 15.40 (+0.14)
The Alliance for Regenerative Medicine Announces Its Third Annual Regen Med Investor Day & Initial Slate of Presenting Companies
GlobeNewswire - Tue Feb 03, 10:44AM CST
via PRWEB - The Alliance for Regenerative Medicine (ARM) today announced its annual Regen Med Investor Day will take place March 25, 2015 in New York City, co-hosted by top financial firm Piper Jaffray. Now in its third year, this one-day meeting remains the only investment event organized specifically to provide institutional, strategic and venture investors with unique insights into the financing hypothesis for advanced therapies-based treatments and technology.
BIIB: 391.66 (-0.45), SGMO: 15.40 (+0.14)
Opko files IND for study of long-acting clotting factor
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 11:31AM CST
BIIB: 391.66 (-0.45), ALNY: 95.54 (+1.67), OPK: 13.80 (-0.28), BAX: 70.39 (+0.31), SGMO: 15.40 (+0.14)
Commit To Buy Sangamo BioSciences At $8, Earn 10.8% Annualized Using Options
at The Street - Thu Jan 22, 10:36AM CST
Investors eyeing a purchase of Sangamo BioSciences Inc shares, but cautious about paying the going market price of $12.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
SGMO: 15.40 (+0.14)
10.0% Return Seen to Date on SmarTrend Sangamo Biosciences Call (SGMO)
Comtex SmarTrend(R) - Wed Jan 21, 5:09PM CST
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on October 28th, 2014 at $12.13. In approximately 3 months, Sangamo Biosciences has returned 10.02% as of today's recent price of $13.34.
SGMO: 15.40 (+0.14)
